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Liver fibrosis is a pathological process in which a pivotal event is the activation of non-parenchymal 
hepatic stellate cells (HSC) into scar-forming liver myofibroblasts in response to parenchymal liver 
cell damage1.  The molecular mechanisms that cross-talk between damaged hepatocytes and non-
parenchymal cells are therefore of significant interest towards discovering novel ways of modulating 
fibrosis progression in patients with chronic liver disease.  Osteopontin (OPN) is a multi-functional 
protein and an important part of the extracellular matrix that has been demonstrated to play many 
important physiological and pathological functions in a wide range of tissues2.  For example OPN 
functions in the regulation of the immune response3,  the modulation of cell proliferation, 
stimulation of angiogenesis, and regulates tumour cell invasion and migration in hepatocellular 
carcinoma4 5.   
 
A growing body of experimental data indicates that OPN also contributes to the injury response of 
the liver and in particular in the fibrogenic process.  In previous work, Nieto and colleagues 
demonstrated that OPN deficient mice display enhanced hepatocyte proliferation and are protected 
from thioacetamide and bile duct ligation-induced liver injury, with impacts on the degree of 
ductular reaction and scarring.  Mechanistically the authors showed effects of OPN on proliferation 
of hepatic progenitor cells and reported enhanced production of collagen-I by HSC via an OPN/TGF-β 
dependant pathway6.  In agreement with these findings, Coombes et al. showed that neutralising 
osteopontin using two different approaches (aptamer and neutralising antibody) abrogated scarring 
in three distinct models of liver fibrosis (carbon tetrachloride (CCl4), methionine-choline deficient 
diet and the 3,5,-diethoxycarbonyl-1,4-dihydrocollidine diet) by modulating TGF-β signalling7.  
Furthermore serum OPN has been identified as a potential prognostic index for reporting 
progression of hepatic fibrosis to cirrhosis and hepatocellular carcinoma8.   
 
In the latest study from the Nieto group, Arriazu et al, through a series of detailed experimental 
approaches, provide important new mechanistic insights into the fibrogenic actions of OPN that 
suggest the existence of both paracrine and autocrine pathways.  Important to their thesis is their 
initial observation of enhanced co-expression, as well as cellular co-localisation, of OPN with an 
important signalling molecule; high mobility group box 1 protein (HMGB1).  This close association 
between OPN and HMGB1 is described in hepatocytes and HSCs in human HCV-induced liver fibrosis 
and in experimental rodent liver fibrosis.  To begin their experimental investigations, the authors 
confirmed that hepatic over-expression of OPN enhances CCl4-induced fibrosis whereas genetic 
deletion of OPN was protective.  A role for HMGB1 in hepatocytes was demonstrated by selective 
deletion in vivo, which resulted in partial protection from CCl4-induced fibrosis.  However, serum ALT 
and AST activities were also lower in these mice possibly indicating an unexplored hepatoprotective 
role for HMGB1 upstream of fibrogenesis.  To interrogate the fibrogenic relationship between OPN 
and HMGB1 the authors carried out a series of elegant co-culture experiments in which they show 
that soluble hepatocyte-derived OPN and HMGB1 stimulate collagen production by HSC.  Moreover, 
OPN was discovered to operate upstream of HMGB1 by inducing its expression and release from 
hepatocytes.  Extracellular HMGB1 acts as a ligand for a number of different pattern recognition 
receptors such as TLRs and RAGE9.  The authors identify RAGE as the key mediator of HMGB1 effects 
on HSC by using lentiviral expression vectors to achieve shRNA knockdown of TLRs 2/4/9 and RAGE 
and then showing that only knockdown of RAGE impacted on HMGB1-induced collagen expression. 
Furthermore, they identify a signalling pathway downstream of RAGE involving activation of the 
intracellular signalling molecules PI3K and pAKT which in turn stimulate collagen-I gene expression. 
Returning to in vivo, the ability of a RAGE neutralising antibody to partially block liver fibrosis 
confirmed the involvement of RAGE. Taken together these experiments nicely describe a novel 
autocrine pathway triggered by OPN/HMGB1 interactions in hepatocytes that result in release of 
extracellular HMGB1 leading to stimulation of collagen expression by HSC via a RAGE/PI3K/pAKT 
dependent pathway (figure 1).  
 
A further key observation was that addition of recombinant OPN (rOPN) to cultured HSC stimulated 
expression of HMGB1 and collagen, an effect that was found to be post-transcriptional.  In addition 
rOPN stimulated translocation of HMGB1 from its usual nuclear location to the cytoplasm and this 
relocation correlated with collagen-I expression.  Nuclear to cytoplasmic shuttling of HMGB1 is at 
least in-part controlled by acetyl-lysine modifications in the protein10 and forced expression of a 
mutated version of HMGB1 lacking these acetyl-lysine residues blocked rOPN-induced collagen 
expression.  Impressively the authors went on to describe the molecular events by which OPN cross-
talks with the regulatory machinery of HMGB1 acetylation.  Briefly, mass spectrometry biochemically 
confirmed that rOPN induces HMGB1 lysine acetylation in HSC and these modifications were 
associated with the selective reduction in histone deactylase 1 and 2 (HDAC1/2) expression 
mediated via NOX-derived ROS. The importance of this pathway was confirmed by showing that 
treatment of HSC with NOX inhibitors blocked rOPN-induced loss of HDAC1/2 expression and also 
inhibited rOPN-induced collagen expression (figure 1). As HSC express both OPN and HMGB1 in 
fibrotic liver these experiments highlight the potential for an autocrine route by which the two 
combine to provoke HSC to produce collagen.  
 
Taken together the various investigational findings of this new study not only reinforce the 
pathophysiological relevance of OPN in liver fibrosis but illuminate HMGB1 as an important 
downstream mediator that orchestrates paracrine and autocrine fibrogenic actions of OPN. 
Additionally, a number of other molecular regulators are identified that may be exploited for drug 
discovery including RAGE, HDAC1/2, NOX, PI3K and pAKTs. However the study also raises a number 
of questions that need to be addressed if the OPN/HMGB1 axis is to be therapeutically manipulated. 
In particular, the relative importance of paracrine versus autocrine signalling is opaque.  Notably the 
authors did not genetically target knockout of OPN or HMGB1 to HSC; the latter being possible via 
several available HSC-selective Cre drivers.  The precise mechanisms by which HSC-expressed 
HMGB1 stimulates collagen expression is also unclear and firm experimental evidence for the 
requirement of HDAC1/2 should be investigated as these proteins have multiple roles with potential 
to impact on collagen expression, as indeed does NOX-derived ROS.  Finally, once in the extracellular 
microenvironment OPN can be cleaved by proteases such as thrombin generating at least two 
different isoforms (OPN-R and OPN-L).  Further there is an intracellular form known as iOPN and 
several alternative splice variants (OPN-a, b and c) have also been described11.  OPN has important 
physiological functions vital to tissue homeostasis and is considered a difficult molecule for 
therapeutic manipulation, however if one or more isoforms are chiefly responsible for OPNs 
fibrogenic activities then selective targeting strategies may emerge. 
 
 
  
Figure legend 
Figure 1 - Proposed mechanism of Osteopontin and HMGB-1 in liver fibrosis 
AC-acetylation, P-Phosphorylation.  
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